Work

Supplemental Figure 1 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 1. A, OS in stage IV KRAS-mutant NSCLC according to KRAS tranversion or transition mutations and LKB1 status. B, OS by different KRAS mutations (G12C vs. G12D)

DOI: 10.1158/1078-0432.22461312

Authors: Antonio Calles, Lynette M. Sholl, Scott J. Rodig, Ashley K. Pelton, Jason L. Hornick, Mohit Butaney, Christine Lydon, Suzanne E. Dahlberg, Geoffrey R. Oxnard, David M. Jackman, Pasi A. Jänne

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361817982

Cites:

Cited by:

Related to: 10